r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement

Similar Items

• bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse
  od: Wooters, Thomas E, i dr.
  Izdano: (2011)
• Repeated Nicotine Administration Robustly Increases bPiDDB Inhibitory Potency at α6β2-containing Nicotinic Receptors Mediating Nicotine-evoked Dopamine Release
  od: Smith, Andrew M., i dr.
  Izdano: (2010)
• Novel bis-, tris-, and tetrakis-tertiary amino analogues as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release
  od: Zhang, Zhenfa, i dr.
  Izdano: (2010)
• Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation
  od: Zheng, Guangrong, i dr.
  Izdano: (2007)
• tetrakis-Azaaromatic quaternary ammonium salts: Novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release
  od: Zhang, Zhenfa, i dr.
  Izdano: (2008)